Medicis shares surge after settlement
The drugmaker says it cuts a deal to end a patent dispute over a generic version of the acne drug Solodyn.
 |
| The companies announced a settlement of the patent dispute over a generic version of the acne drug Solodyn. |
NEW YORK (CNNMoney.com) -- Shares of Medicis Pharmaceutical Corp. rose more than 25% in midday trading Tuesday, following the settlement of a patent dispute with a competitor.
Late Monday, Medicis (MRX) announced it cut a deal with Impax Laboratories Inc., ending a patent dispute over a generic version of the acne drug Solodyn.
At 12:30 p.m. ET, Medicis shares were up $2.81 to $13.93.
According to the announcement, Impax retains the right to market a generic version no later than November 2011. After launching its drug, the conpanies said Impax will pay Medicis a royalty based on sales.
The companies will also collaborate on research and development of five "strategic dermatology product opportunities," including a more advanced version of Solodyn, according to a statement issued by the companies.
The companies said Impax has agreed that Medicis' patents relating to Solodyn are valid and enforceable. 
-
The nation's biggest auto show will be a much more subdued affair. No cattle herds. No open bar. more -
It's not a myth: In places like Detroit and Cleveland, banks are unloading rundown homes for a grand. more -
National Taxpayer Advocate says IRS should ease the burden on already-struggling taxpayers. more -
In a disastrous year for auto sales, here's who came out on top - and who got thrown under the wheels. more -
U.S. households worth more than $1 million have lost nearly a third of their assets. more -
This new $99 pedometer lets you compete online to track fitness goals, sleep, calories. more
